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ABSTRACT 
OBJECTIVE 
To evaluate the relationship between hospital volume and intermediate and long-term patient 
survival for patients undergoing nephrectomy for renal cell carcinoma (RCC). 
 
PATIENTS & METHODS 
Adult RCC patients treated with nephrectomy between 2000 and 2010 were identified from the 
English Hospital Episode Statistics and National Cancer Data Repository. Patients with nodal or 
metastatic disease were excluded. Hospitals were categorised into low (<20/yr), medium (20-39/yr) 
and high (40/yr) volume based on annual cases of RCC nephrectomy.  
 
Multivariable Cox regressions were used to calculate hazard ratios for all-cause mortality by hospital 
volume, adjusting for patient, tumour and surgical characteristics. We assessed conditional survival 
over three follow-up periods: short (30d-1yr), intermediate (1-3yr) and long (3-5yr). We additionally 
explored whether associations between volume and outcomes varied by tumour stage. 
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RESULTS 
12,912 patients were included. Patients in high volume hospitals had 34% reduction in mortality 
risks up to one year compared to those in low volume hospitals (HR 0.66, 95% CI 0.53-0.83, p<0.01). 
Assuming causality, treatment in high volume hospitals was associated with one fewer death in 
every 71 patients treated. Benefit of nephrectomy centralisation did not change with higher T stage 
(p=0.17). No significant association between hospital volume and survival was observed beyond the 
first year.  
 
CONCLUSIONS 
RCC nephrectomy in high volume hospitals was associated with improved survival for up to one year 
after treatment. Our results contribute new insights regarding the value of nephrectomy 
centralisation.  
 
INTRODUCTION 
A volume-outcome relationship in surgery was first proposed by Luft in 1979 with the hypothesis 
that higher surgical volumes and/or greater experience led to lower mortality [1]. Since then, 
numerous studies have reported on the inverse association between hospital volume and patient 
outcomes in a wide range of surgical and medical procedures. This evidence has compelled the 
implementation of volume-based referral strategies, most notably by the Leapfrog Group, a 
watchdog organisation consisted of large corporations and public agencies that purchase healthcare 
in the US [2]. Similar guidance for urological procedures has also been published in the UK in 2002 in 
the Improving Outcomes in Urological Cancer Guidance, where centralisation was recommended for 
radical prostatectomy, cystectomy and in parts for radical nephrectomy where patients have 
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bilateral renal cancer, tumour invading the renal vein or vena cava, or metastatic disease amenable 
to resection [3]. Trends of increasing hospital caseloads have been reported for urological cancer 
operations in different countries, suggesting the general acceptance of surgical centralisation within 
the urology community [4–6]. Evidence to support this change for RCC nephrectomy is however 
based on studies that analysed volume-outcome relationship primarily on short-term perioperative 
results including mortality within 30 days of surgery, complications, length of stay and readmission 
rates [7]. It is currently not well understood how hospital RCC nephrectomy volume is associated 
with patient survival beyond the immediate post-operatively period. Such information can be useful 
for policy makers and healthcare providers to drive care quality improvements, particularly as the 
worldwide incidence of RCC is predicted to rise [8]. In this study, we investigate the volume-outcome 
relationship in renal cancer nephrectomy focusing specifically on survival beyond 30 days.   
 
PATIENTS & METHODS 
Data 
Full data were supplied by Public Health England and contains fields from both English Hospital 
Episode Statics (HES) and National Cancer Data Repository (NCDR). Characteristics of the datasets 
have previously been described, but in short, these are major administrative databases with full 
population coverage containing details of all National Health Service hospital admissions in England 
together with tumour level records and survival information [4]. Ethics approval was granted by the 
National Research Ethics Committee (reference 15/EM/0340) and Confidentiality Advisory Group 
(reference 15/CAG/0169). 
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Exposure Variables 
Patients diagnosed with RCC and treated with either total or partial nephrectomy between 2000 and 
2010 were identified using the International Statistical Classification of Diseases and Related Health 
Problems 10th revision code and Office of Population Censuses and Surveys Classification of 
Interventions and Procedures version code (Supplementary Table 1). We excluded patients aged 17 
or under at the time of surgery as well as those treated with nephroureterectomy or nephrectomy 
of transplanted kidney. A total of 30,763 renal cancer nephrectomies were recorded in the database. 
We further excluded individuals recorded as having had multiple renal cancer operations or bilateral 
procedures. In order to control for differences in tumour stage, only patients with complete TNM 
data were included in our analyses. Patients with nodal or metastatic disease at diagnosis were 
excluded. We analysed only those surviving beyond the initial 30 days after nephrectomy. All 
patients were followed up for death until end of 2015.  
 
Patient level variables included age, sex, ethnicity and socioeconomic deprivation. Comorbidities at 
the time of surgery were tabulated using the Royal College of Surgeons Charlson Score [9]. Type of 
nephrectomy (radical, partial) and surgical access (open, minimally-invasive) were derived from HES 
procedure codes.  
 
Hospital annual operative caseloads were calculated based on the number of nephrectomies 
performed by the responsible hospitals. Our previous study found that the median annual hospital 
nephrectomy volume in England was 23 (IQR 12-39.5) in year 2010 [4].  We therefore categorised 
hospitals into low (LV), medium (MV) and high (HV) volume using practical annual thresholds of 
twenty and forty cases. All 30,763 RCC nephrectomy cases were used for this calculation. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Analysis 
All statistical analyses were performed using Stata 14 [10]. P-values <0.05 were considered 
statistically significant. Differences in patient characteristics amongst the hospital volume categories 
were compared using chi-square tests or analysis of variance. We further explored missing TNM data 
across hospital volumes and other patient characteristics with chi-square tests. 
 
Kaplan-Meier survival estimates of patients treated in different hospital volume categories were 
generated and compared using log-rank test. 
 
Cox proportional hazard regression analyses were used to assess the association between hospital 
nephrectomy volume and survival. Survival time was calculated from date of surgery until date of 
death from any cause. Univariable and multivariable models with appropriate adjustment for 
potential confounders were created. These were identified a priori and included age group (64, 65-
74, ≥75), sex, ethnicity (white, non-white), socioeconomic deprivation, number of comorbidities, 
year of nephrectomy (2000-2002, 2003-2005, 2006-2008, 2009-2010), type of nephrectomy, type of 
surgical access, tumour T stage, tumour grade and histological subtype (clear cell, others). Shared 
frailty Cox models were used to account for clustering of patients within given hospitals and year of 
nephrectomy. We analysed survival over three follow-up periods to determine the effects of hospital 
volume on survival at different post-surgical intervals. They were defined as short (30d to 1yr), 
intermediate (1 to 3yr) and long (3 to 5yr) term. Each period was evaluated conditional on patients 
surviving the previous follow-up interval. We calculated Harrell’s C statistics for each model to assess 
goodness of fit. When significant improvement is demonstrated for HV hospitals, we quantified the 
clinical effectiveness by calculating the numbers needed to treat (NNT) associated with 
centralisation [11]. This number may represent the number of cases that need to be centralised 
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from LV hospitals to HV hospitals in order to prevent one death, assuming that the association is 
causal.  
 
To examine whether missing TNM data could have affected the estimates of the hospital volume-
outcome relationship, we further repeated our analyses only on patients operated between 2009 
and 2010, where TNM coverage was more complete. 
 
Differences in T stages can have significant impact on the nephrectomy complexity and may 
therefore benefit differently from surgical centralisation. We therefore performed subgroup 
analyses based on tumour T stage. To examine whether interaction between hospital volume and T 
stages contribute significantly to the volume-outcome relationship, we also used likelihood ratio test 
to compare multivariable Cox models with and without interaction terms between hospital volume 
and T stage categories. Due to the small number of patients with T4 disease, these were considered 
together with T3 patients.  
 
RESULTS 
A total of 12,912 patients were included in the final analyses with a median follow-up of 8.1 years 
(Supplementary Figure 1). 52.7% of eligible patients were excluded due to unrecorded TNM data. 
Coverage of TNM data varied across hospital volume groups and were less complete for those 
treated in HV hospitals than for patients treated in LV or MV hospitals, but were increasingly 
complete in later years of the study up to 69.0% (Supplementary Table 2).  
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Mean age of the analysis cohort was 63.4 years (range 19 to 95) with 62.6% being male. 
Characteristics of the patients treated in each hospital volume group are described in Table 1. There 
was no difference in the age and sex compositions amongst the hospital volume categories. Patients 
treated in HV hospitals were more likely to have higher numbers of comorbidities. HV hospitals also 
performed higher proportion of partial and minimally invasive surgeries. There were significant 
differences in the T stage distribution amongst hospital volume categories with higher proportion of 
patients in HV hospitals having T1 disease.  
 
Patients in HV hospitals had significantly lower crude unadjusted mortality rates at one, three and 
five years. Kaplan-Meier analysis also demonstrated improved survival between thirty days and five 
years post nephrectomy for patients treated in higher volume hospitals (p<0.01) (Figure 1).  
 
Short-term Survival (30d-1yr) 
In the univariable model, treatment in HV centres resulted in significantly better outcomes 
compared to treatment in LV centres (HR 0.57, CI 0.46-0.70, p<0.01) (Table 2). After adjusting for 
covariates, patients treated in HV centres continued to have better outcomes, with a 34% reduction 
in mortality hazard (HR 0.66, CI 0.53-0.83, p<0.01) (Table 2). A typical patient in HV hospitals had a 
predicted survival probability of 97.4% at one year, compared to 96.0% for a patient in LV hospitals, 
corresponding to NNT of 71 (Figure 2).  
 
As expected, being older, having higher number of comorbidities, higher tumour T stage and grade 
were associated with poorer outcomes. Treatment with partial nephrectomy or minimally invasive 
surgery and treatment in later periods were predictors of improved survival.  
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Intermediate (1-3yr) and Long-term (3-5yr) Survival 
Beyond the first post-operative year, there was no evidence that surviving patients treated in MV or 
HV hospitals had different outcomes compared to LV hospitals (Table 2). Higher age, number of 
comorbidities, tumour T stage and grade remained significant predictors of lower survival, while 
operations in more recent years and with nephron-sparing surgery and minimally invasive access 
continue to be predictors of the reverse. Social deprivation did not consistently affect patient 
survivals.  
 
Restricted Cohort 
To examine whether missing TNM data affected our results, we repeated our analyses on patients 
treated between 2009 and 2010. In this restricted cohort, TNM data was available for 69.0% of the 
eligible patients, compared to 47.3% in the entire cohort.  
 
Results remained consistent with patients treated in HV hospitals having a 36% reduction in 
mortality hazard in the first year compared to those treated in LV hospitals (HR 0.64, CI 0.43-0.94, 
p=0.02) (Table 2). No association between hospital volume and survival was observed after one year.  
 
T Stage Subgroup Analyses 
During the short-term follow-up period between 30d to 1yr, treatment in HV hospitals were seen to 
improve survival for patients with T1 (HR 0.57, CI 0.33-0.97, p=0.04) and T2 (HR 0.41, CI 0.20-0.83, 
p=0.01) disease (Table 3). These corresponded to NNT of 143 and 37 respectively, assuming 
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causality. No significant association was observed between hospital volume and survival for patients 
with T3 or T4 disease or beyond the first year of follow-up. However, difference between 
“significant” and “not significant” is not itself statistically significant and when examined using 
likelihood ratio test, there was no statistical evidence of interaction between hospital volume and T 
stage categories (p=0.17).  
 
DISCUSSION 
In this study, we found that a survival benefit exists for RCC patients treated in HV hospitals up to 
one year after nephrectomy. Benefit beyond the first year of follow-up was not observed. Patient 
age, number of comorbidities, tumour T stage and grade at time of surgery remained significant 
predictors of long-term survival, although there was no evidence that particular T stage benefited 
preferentially to surgical centralisation.  
 
The effect of hospital volume on RCC patient outcomes has been a subject of interest and well 
characterised in widespread publications in recent years [12–15]. Most of these studies have 
concluded that higher hospital volume correlates to better outcomes particularly during the 
perioperative period. Our previous meta-analysis on the effect of radical nephrectomy centralisation 
showed that HV hospitals reduced surgical mortality risks by 26% and complications by 18% 
compared to LV hospitals [7]. Due to the relatively low mortality rates associated with RCC 
nephrectomy, we suggested that the perceived clinical benefit of centralisation was however 
marginal. Longer-term survival in this instance may therefore represent more appropriate outcome 
measure, particularly as one and five-year survival are more often used as benchmarks for assessing 
the efficacy of oncological treatment.  
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Similar findings of improved long-term oncological outcomes in HV centres have been reported in 
other cancer resections including those for breast and oesophageal cancer and pancreatic ductal 
adenocarcinoma [16–18]. Hospital volume should however be viewed as a proxy measure for 
healthcare quality encompassing the quality of surgical treatment and pre and post-operative care, 
but does not in itself identify the exact aspects and practices of HV hospitals that drive the observed 
association to survival. There are several mechanisms that could explain our findings. First, surgeons 
in HV hospitals have greater experience and skills in RCC nephrectomy resulting in lower 
perioperative morbidity and therefore reduced one-year mortality. Second, HV hospitals may also 
have more streamlined perioperative pathways that contribute to the improved short-term 
outcomes. Third, greater patient exposure by the complementary multidisciplinary team including 
radiologists and oncologists may also lead to improvements in detecting disease relapse facilitating 
more timely interventions. Fourth, larger centres also often have the required infrastructure to 
enable quicker adoption of new clinical guidelines and greater access to novel treatments including 
clinical trials, although this may not be as relevant in our cohort which focused only on patients with 
localised disease at time of nephrectomy. The association between hospital volume and survival 
attenuated after adjustments for patient-level characteristics suggesting a role of case-mix in 
explaining the crude variation, but also indicating that case-mix alone is unlikely to explain the whole 
difference.  
 
Our findings are suggestive of the presence of a volume-outcome relationship for RCC nephrectomy 
across volume categories, with patients treated by hospitals with higher activity having lower risks of 
mortality, consistent with previous studies examining volume-outcome relationships in patients with 
lung, bladder and stomach cancer [19,20]. The body of prior evidence and our own findings support 
that centralising nephrectomy activity for RCC is associated with improved survival beyond the 
immediate post-operative period.  
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To further contextualise the effect of surgical centralisation on RCC nephrectomy, we calculated 
NNT. Assuming causality and that patients treated in LV centres had the same outcomes as those 
treated in HV centres, prevention of one death in the first year could be realised after centralising 71 
patients. This is substantially lower than the 234 patients estimated in our previous review that is 
required to be centralised to prevent one perioperative death, and may therefore represent 
stronger evidence to support RCC nephrectomy centralisation [7].  
 
Positive volume-outcome relationship is more likely to be observed in technically challenging 
procedures that carry higher morbidities and mortalities. It is therefore surprising that T stage did 
not affect the benefit of nephrectomy centralisation in our analyses, particularly as T3 and T4 
represent advanced disease with perinephric invasion. It is plausible that T3 and T4 patients have 
generally poorer prognosis diminishing the effect of hospital volumes, as evident in the higher point 
estimate for hazard ratio. Our stage-specific sample size may also not be sufficient to detect 
statistical significance in individual subgroups.   
 
To the best of our knowledge, this is currently the only study to describe the association between 
hospital volume and RCC nephrectomy survival beyond the immediate postoperative period. Other 
strengths of our study include the use of data with whole population coverage with all patients 
followed up for a minimum of five years. Patient reporting in HES and NCDR are mandatory leading 
to case ascertainment of >98% [21]. Linkage of the two databases also allowed patient, hospital and 
tumour level variables to be included in our statistics model resulting in improved model fits. Using 
patient data from England where the healthcare system relies more on regional network referral and 
where patients have less choice on their treatment doctors, selective referral where high performing 
hospitals are more likely to receive further cases, is less likely to be a confounding factor.  
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There are several limitations to our study. There is potential selection bias in our study as a 
significant proportion of our cohort had incomplete TNM records. However, we observed consistent 
results when analyses were repeated on a restricted cohort with significantly more complete TNM 
data coverage. Use of adjuvant or neoadjuvant systemic therapy were not recorded in NCDR and 
were therefore not adjusted in our analyses. While systemic therapy can have significant impact on 
long-term survival, these have not traditionally been advocated for patients with localised disease 
for which our study focused exclusively on. We measured the effect of hospital volume on overall 
survival, but did not control for the differences in background mortality. It is possible that patients 
treated by different volume hospitals had different non-renal cancer mortality risks, although 
adjustment for comorbidities mitigated these concerns.  
 
Future research should focus on identifying the exact quality and process of care in HV centres that 
drive outcome improvements, allowing lower performing hospitals to adopt these practices. In the 
era of centralisation, guidelines have been published on the volume threshold that hospitals should 
achieve annually. Yet these have been based on very limited evidence and there is currently no 
consensus on the definition of HV hospital. More study should therefore focus on ascertaining the 
minimum number of nephrectomy that providers should carry out to attain acceptable outcomes.  
  
In this analysis of volume-outcome relationship, we further characterised the survival benefit of RCC 
nephrectomy centralisation and found that improvement exists beyond the immediate perioperative 
period and extends to one year after surgery. Our results contribute to the growing evidence in 
support of nephrectomy centralisation for RCC patients.  
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Table 1: Patient characteristics stratified by hospital volume categories. CCI Charlson Comorbidities, IMD Index of Multiple Deprivation.
LV Hospital (<20) MV Hospital (20-39) HV Hospital (≥40) P Value
n 4,468 5,309 3,135
Number of hospitals 146 96 42
Mean age (yr) (range) 63.6 (19-93) 63.4 (19-95) 63.2 (20-92) 0.33
Male (%) 63.2 62.5 61.9 0.51
White (%) 84.9 88.5 91.7 <0.01
CCI 
    0 (%) 64.8 61 58.9
    1 (%) 25.8 27.8 28.1
    ≥2 (%) 9.4 11.3 13
IMD
    1 – Least Deprived (%) 20.3 17.6 20.4
    2 (%) 23.3 22.8 21.9
    3 (%) 21.8 23.3 23
    4 (%) 20.4 20 18.5
    5 – Most Deprived (%) 14.3 16.3 16.1
Nephrectomy Type
    Radical nephrectomy (%) 95.8 90.1 83.4
    Partial nephrectomy (%) 4.2 9.9 16.6
Minimally-invasive access 
(%)
19.4 33.6 44.8 <0.01
T Stage
    T1 (%) 42.4 47.6 50.9 <0.01
    T2 (%) 23.6 18.7 15.4 <0.01
    T3/T4 (%) 34.1 33.8 33.7 0.91
Grade
    1 (%) 11.3 8.6 5.8
    2 (%) 48.6 47 45.1
    3 (%) 32 34.7 36.4
    4 (%) 8.2 9.6 12.7
Morphology
    Clear cell (%) 92.7 91 90.8
    Others (%) 7.3 9 9.2
Mortality
    1-year (%) 8.8 7.1 5.4 <0.01
    3-year (%) 20.3 18.3 14.6 <0.01
    5-year (%) 28.6 25.8 22.6 <0.01
<0.01
<0.01
<0.01
<0.01
0.15
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Table 2: Univariable and multivariable Cox proportional hazard regression models with shared frailty examining conditional survival over 
three follow-up periods for patients treated in three hospital nephrectomy volume categories. Restricted cohort consisted of patients treated 
in 2009 and 2010 analysed separately showing consistent results. CCI Charlson Comorbidities. IMD Index of Multiple Deprivation.
Variables
Hospital 
Volumes
<20 Ref Ref Ref
20-39 0.77 0.66-0.90 <0.01 0.96 0.84-1.09 0.5 0.88 0.76-1.02 0.09
≥40 0.57 0.46-0.70 <0.01 0.75 0.64-0.88 <0.01 0.89 0.75-1.06 0.2
C-Index
Hospital 
Volumes
<20 Ref Ref Ref
20-39 0.87 0.74-1.03 0.11 1.05 0.93-1.20 0.42 0.95 0.81-1.11 0.5
≥40 0.66 0.53-0.83 <0.01 0.86 0.73-1.01 0.07 1.01 0.83-1.22 0.93
Age
 Ref Ref Ref
65-74 1.19 1.00-1.41 0.04 1.31 1.16-1.49 <0.01 1.41 1.21-1.64 <0.01
≥75 1.51 1.25-1.81 <0.01 1.76 1.54-2.01 <0.01 2.43 2.08-2.84 <0.01
Sex
Male Ref Ref Ref
Female 1.09 0.93-1.27 0.28 0.93 0.83-1.04 0.22 0.84 0.73-0.96 0.01
Ethnicity
White Ref Ref Ref
Non-white 0.8 0.54-1.16 0.24 0.85 0.65-1.11 0.24 0.74 0.54-1.02 0.07
CCI
0 Ref Ref Ref
1 2 1.69-2.37 <0.01 1.75 1.55-1.97 <0.01 1.39 1.20-1.60 <0.01
≥2 3.39 2.79-4.13 <0.01 2.35 2.02-2.73 <0.01 2.13 1.78-2.55 <0.01
IMD
1 Ref Ref Ref
2 1.06 0.84-1.33 0.63 0.94 0.80-1.11 0.48 1.02 0.84-1.25 0.81
3 1.11 0.88-1.39 0.37 1.03 0.87-1.21 0.72 1.03 0.84-1.25 0.8
4 1.28 1.02-1.60 0.04 1.05 0.89-1.24 0.57 1.18 0.96-1.45 0.11
5 1.06 0.81-1.37 0.67 1.04 0.87-1.25 0.64 1.26 1.02-1.56 0.03
Year
2000-2002 Ref Ref Ref
2003-2005 0.82 0.65-1.04 0.11 0.88 0.73-1.105 0.16 0.78 0.62-0.99 0.04
2006-2008 0.79 0.62-1.00 0.05 0.74 0.61-0.89 <0.01 0.78 0.62-0.98 0.03
2009-2010 0.67 0.52-0.88 <0.01 0.65 0.53-0.79 <0.01 0.7 0.55-0.89 <0.01
T stage
1 Ref Ref Ref
2 1.54 1.19-2.00 <0.01 1.62 1.37-1.91 <0.01 1.34 1.12-1.61 <0.01
3 3.13 2.54-3.85 <0.01 2.61 2.27-3.00 <0.01 1.92 1.65-2.23 <0.01
4 11.65 8.30-16.37 <0.01 4 2.64-6.06 <0.01 3.56 2.06-6.15 <0.01
Grade
1 Ref Ref Ref
2 0.66 0.45-0.95 0.03 1.2 0.91-1.58 0.21 0.94 0.72-1.22 0.62
3 1.45 1.01-2.08 0.04 1.74 1.32-2.31 <0.01 1.34 1.03-1.75 0.03
4 2.5 1.71-3.65 <0.01 3.45 2.56-4.64 <0.01 1.49 1.08-2.05 0.02
Morpholog
y
Clear Cell Ref Ref Ref
Others 1 0.59-1.71 0.99 1.19 0.86-1.65 0.29 1.1 0.75-1.61 0.62
Nephrecto
my Type
Radical Ref Ref Ref
Partial 0.33 0.18-0.59 <0.01 0.58 0.43-0.77 <0.01 0.52 0.38-0.71 <0.01
Surgical 
access
Open Ref Ref Ref
Minimally 
Invasive
0.69 0.56-0.85 <0.01 0.71 0.61-0.81 <0.01 0.77 0.66-0.90 <0.01
C-Index
Hospital 
Volumes
<20 Ref Ref Ref
20-39 0.72 0.50-1.03 0.07 1.13 0.84-1.53 0.42 1.18 0.84-1.66 0.33
≥40 0.64 0.43-0.94 0.02 0.95 0.69-1.31 0.75 1.22 0.86-1.75 0.27
C-Index
Univariable Model
Multivariable Model
Short Intermediate Long
(30d-1yr) (1-3yr) (3-5yr)
0.56 (0.53-0.58) p<0.01 0.53 (0.51-0.54) p<0.01 0.51 (0.50-0.53) p<0.01
Multivariable Model (2009-2010 Cohort)
0.80 (0.77-0.83) p<0.01 0.75 (0.73-0.77) p<0.01 0.74 (0.72-0.77) p<0.01
HR 95% CI p Value
0.79 (0.78-0.80) p<0.01 0.73 (0.72-0.75) p<0.01 0.70 (0.69-0.72) p<0.01
HR 95% CI p Value HR 95% CI p Value
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Table 3: Multivariable Cox proportional hazard regression models with shared frailty examining conditional survival over three follow up 
periods for patients with localised RCC stratified by T stages.
Hospital
Volume
<20 Ref Ref Ref
20-39 0.69 0.45-1.04 0.07 1.03 0.79-1.36 0.82 1.04 0.81-1.35 0.76
≥40 0.57 0.33-0.97 0.04 0.88 0.62-1.26 0.49 0.98 0.70-1.37 0.89
<20 Ref Ref Ref
20-39 0.55 0.36-0.84 0.01 0.96 0.73-1.26 0.76 0.84 0.60-1.17 0.3
≥40 0.41 0.20-0.83 0.01 0.65 0.44-0.95 0.03 0.93 0.60-1.46 0.76
<20 Ref Ref Ref
20-39 0.98 0.79-1.21 0.87 1.09 0.92-1.29 0.31 0.91 0.71-1.15 0.42
≥40 0.77 0.58-1.02 0.07 0.9 0.73-1.11 0.31 1.05 0.79-1.39 0.75
HR 95% CI p Value
T1
T2
95% CI p Value
T3/T4
HR 95% CI p Value HR
Short Intermediate Long
(30d-1yr) (1-3yr) (3-5yr)
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